Based On The Effect Of The Triple Viable Bifidobacterium On The Intestinal Flora Of Patients With Coronary Heart Disease And The Correlation Analysis Of The Prognosis

Objective:The clear risk factors for coronary heart disease(CHD)include age and sex,smoking history,dyslipidemia,hypertension,diabetes,and obesity.Bifidobacterium triple viable bacteria is a commonly used probiotic preparation in clinical practice.This article aims to analyze its influence on the number of various intestinal flora in patients with coronary heart disease and three major risk factors such as blood lipids,blood sugar and blood pressure.Methods:Patients who were diagnosed with coronary heart disease by coronary angiography in the Affiliated Hospital of Qingdao University from June 2019 to December 2020 will be included as experimental subjects.The target number of patients with coronary heart disease without comorbidities is 100.The plan is to divide them into an observation group with a target number of 50 cases,and a control group with a target number of 50 cases.All patients were treated with conventional coronary heart disease treatment programs(statin lipid lowering,dual antiplatelet and coronary expansion,etc.).Observation group 1 was treated with bifidobacterium triple viable enteric-coated capsules on this basis for 12 weeks of continuous treatment.Instruct all selected patients to maintain their pre-medication diet and lifestyle during medication.Detect the patient’s HDL-C,LDL,TC,TG and the number of various intestinal flora in feces before medication,and re-test related indicators after 12 weeks.The target number of patients with diabetes and coronary heart disease is 60 cases.The 60 cases are planned to be divided into observation 2 groups and control 2 groups,and the target number is 30 cases each.All patients were given the same coronary heart disease treatment plan as in group 1,and were given the same blood sugar-lowering plan.On this basis,it was observed that the two groups were treated with the same course of live bacteria as the first group.During the follow-up process,both the observation group and the control group had patients in the observation group and the control group who adjusted their hypoglycemic program and withdrew from the study due to poor blood glucose control,and re-entered new patients until the target number of patients was completed.The fasting blood glucose,two-hour postprandial blood glucose,glycosylated hemoglobin,and the number of various intestinal flora in the stool were tested in the same way as in the first group,and the relevant indicators were retested after 12 weeks.The target number of patients with hypertension and coronary heart disease is 60 cases.The 60 cases are divided into observation 3 groups and control 3 groups,and the target number is 30 cases.All patients were given the same coronary heart disease treatment plan as group 1 and were given the same blood pressure lowering plan.On this basis,it was observed that 3 groups added live bacteria with the same course of treatment as group 1 and the blood pressure reduction plan was adjusted due to poor blood pressure control.Of patients withdrew from the study.Measure the patient’s early morning blood pressure and the number of various intestinal flora in the feces before the medication,pay attention to multiple measurements at different times and take the average value,and repeat the measurement after 12 weeks of treatment.Comparing the differences of the intestinal flora and various indicators between the three groups of observation group and the three groups of control group before and after treatment,P<0.05 indicates that the difference is statistically significant.Results:1.In terms of various types of intestinal flora,before treatment,there was no difference in the number of feces of the three observation groups and the control group(P>0.05).After treatment,the bifidobacteria,bifidobacteria,Lactobacillus was significantly higher than the same group before treatment(P<0.05),and higher than the control group after treatment(P<0.05);while the number of enterococci decreased,the difference was also significant(P<0.05).2.In the blood lipid-related indicators,there was no statistical difference between the observation group and the control group before treatment(P>0.05);after treatment,compared with the control group,the total cholesterol(TC)of the observation group was lower than that of the control group.Low density lipoprotein cholesterol(Low density lipoprotein cholesterol,LDL-C)two groups of indicators were significantly reduced,and the P value was less than 0.05,which was statistically significant.High density lipoprotein cholesterol(HDL-C)Compared with triglyceride(TG),there was no significant decrease in the control group,and the P values were all >0.05,which was not statistically significant.3.Blood glucose related indexes,the observation group and the control group had no significant difference in blood glucose,glycosylated hemoglobin and fasting blood glucose at 2h after meal before treatment(P>0.05);after treatment,the blood glucose indexes of the observation group were compared with those of the control group Significantly decreased,and their P values were all <0.05.4.Compared with the control group,the blood pressure values of the observation group were not statistically different before and after treatment,whether it was systolic blood pressure or diastolic blood pressure,their P values were all>0.05.Conclusions:The triple viable bifidobacterium has a significant regulatory effect on the intestinal flora of patients with coronary heart disease,which can increase the number of bifidobacteria and lactobacilli,and reduce the number of enterococci.On the basis of standardized treatment,it can further improve its lipid metabolism and blood sugar level,and can be used clinically to assist in the treatment of coronary heart disease.